^
    Back
    Association details:
    Biomarker:HR positive + HER-2 amplification
    Cancer:HER2 Positive Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

    Excerpt:
    Evaluate response, in patients with tumors that demonstrate hormone receptor (HR)-positivity (> 1% on immunohistochemistry [IHC]) and human EGF receptor 2 (HER)-positivity (IHC 3 and/or IHC 2/3 and fluorescence in situ hybridization [FISH] amplification).
    Trial ID:
    PerELISA
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Phase I study of everolimus, letrozole, and trastuzumab in patients with hormone receptor-positive metastatic breast cancer or other solid tumors

    Published date:
    10/28/2020
    Excerpt:
    Five breast cancer patients (4 with HER2amplification and 1 with HER2mutation) had partial responses....Everolimus, letrozole, and trastuzumab has a favorable safety profile and elicits encouraging signals of anticancer activity in patients with heavily pretreated hormone receptor-and HER2-positive advanced cancers.
    Secondary therapy:
    everolimus + letrozole
    DOI:
    10.1158/1078-0432.CCR-20-2878
    Trial ID:
    PerELISA